

Hansen Dang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4285493/publications.pdf>

Version: 2024-02-01

11
papers

223
citations

1307366

7
h-index

1588896

8
g-index

11
all docs

11
docs citations

11
times ranked

422
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 538-540.e4.	2.4	2
2	Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2021, 5, 122-132.	2.0	19
3	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. <i>American Journal of Gastroenterology</i> , 2021, 116, 1264-1273.	0.2	12
4	Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. <i>Hepatology</i> , 2021, 74, 656-666.	3.6	31
5	Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , 2020, 71, 1910-1922.	3.6	70
6	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	1.9	38
7	497 "Hcv Cure by Ifn-Free Direct Acting Antivirals (DAAS) are Associated with Increased Survival in Patients with Hcvrelated Hcc: A Real-World, Propensity Score-Matched Cohort Study from the U.S. and Japan. <i>Gastroenterology</i> , 2019, 156, S-1200-S-1201.	0.6	0
8	Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015. <i>Cancer</i> , 2018, 124, 2588-2598.	2.0	36
9	Tu1494 - Effects of Screening in Nonalcoholic Fatty Liver Disease and Cryptogenic Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, S-1238.	0.6	0
10	Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. <i>Scientific Reports</i> , 2018, 8, 7164.	1.6	15
11	Metabolic Risk Factors Increase the Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Cirrhosis. <i>Gastroenterology</i> , 2017, 152, S1077.	0.6	0